{"organizations": [], "uuid": "9495ca3ec90b4906655a6b912d1e3740339fdfc8", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-therapix-biosciences-says-us-fda-c/brief-therapix-biosciences-says-u-s-fda-cleared-ind-for-thx-110-in-treatment-of-chronic-low-back-pain-idUSFWN1R20JQ", "country": "US", "domain_rank": 408, "title": "BRIEF-Therapix Biosciences Says U.S. FDA Cleared IND For THX-110 In Treatment Of Chronic Low Back Pain", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-20T16:14:00.000+02:00", "replies_count": 0, "uuid": "9495ca3ec90b4906655a6b912d1e3740339fdfc8"}, "author": "", "url": "https://www.reuters.com/article/brief-therapix-biosciences-says-us-fda-c/brief-therapix-biosciences-says-u-s-fda-cleared-ind-for-thx-110-in-treatment-of-chronic-low-back-pain-idUSFWN1R20JQ", "ord_in_thread": 0, "title": "BRIEF-Therapix Biosciences Says U.S. FDA Cleared IND For THX-110 In Treatment Of Chronic Low Back Pain", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "brief-therapix biosciences says u.s. fda", "sentiment": "negative"}, {"name": "treatment of chronic low back pain reuters staff   therapix biosciences ltd", "sentiment": "none"}, {"name": "fda", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 20, 2018 / 2:14 PM / Updated 29 minutes ago BRIEF-Therapix Biosciences Says U.S. FDA Cleared IND For THX-110 In Treatment Of Chronic Low Back Pain Reuters Staff March 20 (Reuters) - Therapix Biosciences Ltd: * THERAPIX BIOSCIENCES - U.S. FDA CLEARED IND FOR THX-110 IN TREATMENT OF CHRONIC LOW BACK PAIN * THERAPIX BIOSCIENCES - EXPECTS TO COMMENCE PHASE IIA CLINICAL TRIAL FOR CHRONIC LOW BACK PAIN DRUG DURING Q2 2018 Source text: ( bit.ly/2GMdJ8D ) Further company coverage:", "external_links": [], "published": "2018-03-20T16:14:00.000+02:00", "crawled": "2018-03-20T16:33:41.008+02:00", "highlightTitle": ""}